Published on February 11, 2010 at 1:22 AM
Principio Inc., a privately held emerging company developing novel
molecular imaging agents and therapeutic radiopharmaceuticals for the
treatment of cancer, today announced that the Company has obtained an
exclusive license to several technologies developed at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center.
“We are extremely delighted to have obtained exclusive rights to these
novel, revolutionary, and much needed imaging and radiotherapeutic
molecules. We will move quickly to commercialize these much needed
therapies for these devastating cancers”
The molecules include novel imaging and radiotherapeutic agents for
Epstein Barr Virus (EBV) associated tumors and prostate cancer. The EBV
technology, published in the October 2008 issue of the journal Nature
Medicine, leverages a specific enzyme produced by the virus to allow for
the imaging and therapy of the tumors caused by the virus, which include
numerous lymphomas, stomach cancer, nasopharyngeal cancers, and most
AIDS related lymphomas.
Under the terms of the agreement, the license gives Principio exclusive,
worldwide rights to commercialize these much needed imaging agents and
therapy. Further details of the agreement were not disclosed.
"We are extremely delighted to have obtained exclusive rights to these
novel, revolutionary, and much needed imaging and radiotherapeutic
molecules. We will move quickly to commercialize these much needed
therapies for these devastating cancers," stated Joe Hernandez, Founder
and CEO of Principio.
SOURCE Principio Inc.,